Analysts expect The Cooper Companies, Inc. (NYSE:COO) to post $2.83 earnings per share for the current fiscal quarter, Zacks reports. Nine analysts have issued estimates for The Cooper Companies’ earnings. The highest EPS estimate is $2.85 and the lowest is $2.81. The Cooper Companies posted earnings per share of $2.50 during the same quarter last year, which would indicate a positive year-over-year growth rate of 13.2%. The company is scheduled to announce its next earnings results on Thursday, June 7th.
According to Zacks, analysts expect that The Cooper Companies will report full-year earnings of $11.82 per share for the current fiscal year, with EPS estimates ranging from $11.74 to $11.87. For the next financial year, analysts forecast that the firm will report earnings of $12.65 per share, with EPS estimates ranging from $11.90 to $12.98. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover The Cooper Companies.
The Cooper Companies (NYSE:COO) last announced its quarterly earnings results on Thursday, March 8th. The medical device company reported $2.79 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.51 by $0.28. The business had revenue of $590.00 million during the quarter, compared to the consensus estimate of $583.07 million. The Cooper Companies had a net margin of 7.83% and a return on equity of 16.90%. The business’s revenue was up 18.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.93 EPS.
In other The Cooper Companies news, CEO Robert S. Weiss sold 36,769 shares of the firm’s stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $242.35, for a total value of $8,910,967.15. Following the completion of the transaction, the chief executive officer now owns 135,936 shares of the company’s stock, valued at approximately $32,944,089.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Carol R. Kaufman sold 13,362 shares of the firm’s stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $243.88, for a total transaction of $3,258,724.56. Following the completion of the transaction, the executive vice president now directly owns 59,305 shares of the company’s stock, valued at approximately $14,463,303.40. The disclosure for this sale can be found here. Insiders have sold a total of 56,581 shares of company stock valued at $13,645,387 in the last ninety days. 1.60% of the stock is currently owned by corporate insiders.
Hedge funds have recently modified their holdings of the business. California Public Employees Retirement System boosted its position in The Cooper Companies by 11.4% in the 3rd quarter. California Public Employees Retirement System now owns 120,582 shares of the medical device company’s stock valued at $28,591,000 after buying an additional 12,382 shares during the period. Schroder Investment Management Group boosted its position in The Cooper Companies by 3.4% in the 4th quarter. Schroder Investment Management Group now owns 414,626 shares of the medical device company’s stock valued at $90,339,000 after buying an additional 13,442 shares during the period. Wells Fargo & Company MN boosted its position in The Cooper Companies by 41.5% in the 4th quarter. Wells Fargo & Company MN now owns 250,479 shares of the medical device company’s stock valued at $54,574,000 after buying an additional 73,427 shares during the period. Stifel Financial Corp boosted its position in The Cooper Companies by 10.9% in the 3rd quarter. Stifel Financial Corp now owns 12,065 shares of the medical device company’s stock valued at $2,857,000 after buying an additional 1,181 shares during the period. Finally, BlackRock Inc. boosted its position in The Cooper Companies by 1.5% in the 4th quarter. BlackRock Inc. now owns 3,616,339 shares of the medical device company’s stock valued at $787,926,000 after buying an additional 54,380 shares during the period. 98.53% of the stock is owned by institutional investors.
Shares of NYSE COO traded down $5.57 during midday trading on Friday, reaching $217.98. 298,060 shares of the stock were exchanged, compared to its average volume of 551,784. The company has a market capitalization of $10,685.60, a P/E ratio of 22.47, a P/E/G ratio of 1.71 and a beta of 0.62. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.83 and a quick ratio of 1.61. The Cooper Companies has a twelve month low of $194.55 and a twelve month high of $260.26.
The Cooper Companies Company Profile
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for The Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.